_?_ schreef op 21 augustus 2018 22:17:
All these factors have no doubt contributed to high – some might say overinflated – expectations for lanadelumab. But, with pricing a sensitive topic right now, Shire will have to tread carefully.
Interestingly the US pricing watchdog Icer has already begun evaluating the project, along with other prophylactic HAE therapies, with a report expected in October. Bernstein analysts say the Icer report and resistance from payers are among the biggest potential stumbling blocks for lanadelumab.
When asked about pricing last week Mr Ornskov would only say that lanadelumab would be a “significantly higher-margin product” than Shire’s existing HAE drugs, so even at a slight discount to Cinryze lanadelumab could be more profitable. At around $350,000 per year, according to the US pharmacy chain CVS Health, Cinryze is not exactly cheap.
The HAE landscape could change again soon, with a US approval decision due for Pharming’s Ruconest for prophylactic use by September 21. Still, this is an intravenous therapy, so lanadelumab should still have the edge on convenience. Ruconest is already approved for acute use in HAE.
www.evaluate.com/vantage/articles/eve...